Plain-English translation of NCT04793737 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether combining precision radiation therapy (a focused, high-dose radiation treatment) with PD-1 inhibitor medications like pembrolizumab or nivolumab can help people whose melanoma has stopped responding to the immune therapy alone. Researchers want to see if the radiation can help restart the immune system's ability to fight the cancer, even in areas that aren't being radiated directly.
Many people with advanced melanoma initially respond well to immune checkpoint therapy, but eventually their cancer becomes resistant and starts growing again. This trial exists to find out whether combining this medication with targeted radiation might overcome that resistance and give patients another way to fight back.
You likely qualify if…
You likely don't qualify if…
You would receive precision radiation therapy to one or more of your melanoma tumors while continuing to take your PD-1 inhibitor medication (pembrolizumab or nivolumab). After the radiation is completed, you would continue the immune therapy for up to one year and have regular follow-up appointments with imaging scans. The study would track your progress for 24 months or until your disease worsens or the study ends.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Sweden
Sponsor
Karolinska University Hospital
Enrollment target
~27 participants
Started
March 2021
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hildur Helgadottir, MD, PhD
Karolinska University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.